
Which Sleep Apnea Patients Benefit Most from Zepbound?
A 2026 secondary analysis of the SURMOUNT-OSA trial identified a strong response endotype for tirzepatide in obstructive sleep apnea. These patients may experience nearly double the AHI reduction, moving from trial-wide averages to more personalized expectations.










